Table 1

Computation of rates of chronic obstructive pulmonary disease (COPD) exacerbations requiring health care use (HCU) and of pneumonias in the INSPIRE trial, along with rate differences comparing the fluticasone–salmeterol combination with tiotropium5 6

Fluticasone + salmeterolTiotropiumRate difference* (per 100/year)
Number of subjects658665
Days on treatment (mean)561519
Person-years on treatment (total)1011945
Number of exacerbations (HCU†)11851070
 Rate per year (per 100)117.2113.2+4.0
Number of pneumonias6225
 Rate per year (per 100)6.12.6+3.5
  • *Rate difference = rate for fluticasone–salmeterol combination minus rate for tiotropium.

  • †Exacerbations requiring health care use.